By acquiring Amylin Pharmaceuticals Inc. (NASDAQ:AMLN), Bristol-Myers Squibb Co. (NYSE:BMY) will add three marketed drugs plus at least four clinical-stage diabetes products. Following the acquisition, BMS and AstraZeneca plc (LSE:AZN; NYSE:AZN) will fold the Amylin compounds into their 2007 diabetes partnership covering Onglyza saxagliptin and Forxiga dapagliflozin. In exchange, AstraZeneca will make a $3.4 billion cash payment to BMS's Amylin subsidiary.

AstraZeneca or BMS products that do not fall under the original 2007 deal could be included in the alliance at a later date